Patient Medication Instructions for Aceminid

Drug name: Asciminib (Asciminib)

Drug category: third-generation tyrosine kinase inhibitors (TKI)

1.Indications:

Aximini is indicated for the treatment of patients with chronic myelogenous leukemia (CML) who are resistant to or intolerant to first- and second-generation TKIs, particularly those carrying the T315I mutation. The drug can effectively inhibit the proliferation of tumor cells by targeting the myristoyl binding pocket of BCR-ABL kinase.

2.Mechanism of action

Aximini blocks the signaling of abnormal cell proliferation by inhibiting the myristoyl pocket of the BCR-ABL fusion protein, thereby slowing down or preventing the spread of leukemia cells. Unlike traditional TKI drugs, aximini targets different binding sites, which makes it effective for patients with drug-resistant mutations, especially those with T315I mutations.

3.Medicine usage

Recommended dose: The generally recommended dose is 40mg twice a day, approximately 12 hours apart. If the patient is a T315I mutation carrier, the dose is 200 mg twice daily.

How to take: The tablet should be swallowed whole and should not be chewed or broken. It can be taken with food or on an empty stomach. Take it with water and avoid taking it with acidic foods or drinks (such as orange juice, soda water) to avoid affecting the absorption of the drug.

Handling of missed doses: If the patient forgets to take the medicine and it is more than 6 hours before the next dose, the patient can take it in time. If it is less than 6 hours before your next dose, skip the missed dose and do not double the dose.

4.Taboos and Precautions

Contraindicated in patients allergic to aceminib or any of its components.

Pregnant and lactating women: Aceminid may have adverse effects on the fetus or infant, so pregnant women or women planning to become pregnant should take effective contraceptive measures when using Aceminid. Breastfeeding women should avoid breastfeeding while taking this medication.

Hepatic Impairment: Patients with hepatic impairment need to be particularly careful when using aceminib and may need to adjust the dose and regularly monitor liver function.

Drug interactions: Aceminid may interact with certain drugs, including certain antibiotics, antifungal drugs, anti-epileptic drugs, etc. You should inform your doctor of all drugs you are taking before use.

5.Adverse reactions

The side effects of Aceminib are generally controllable. Common adverse reactions include:

Hematological adverse reactions: such as thrombocytopenia, neutropenia, anemia, etc. Regular blood tests are recommended to monitor changes in the blood picture.

Gastrointestinal discomfort: including nausea, vomiting, diarrhea, loss of appetite, etc. These symptoms are usually mild and may lessen over time.

Abnormal liver function: Patients taking aceminib may experience elevated liver function indicators. Regular monitoring of liver function is very important.

Fatigue: Fatigue is a common side effect and patients should get adequate rest.

Skin rash: Some patients may develop mild to moderate rash, which can be relieved with anti-allergic drugs if necessary.

Hypertension: Aceminid may cause an increase in blood pressure. Patients are advised to monitor their blood pressure regularly and control high blood pressure under the guidance of a doctor.

6.Medication Monitoring

During the use of Asiminib, patients should undergo the following examinations regularly:

Blood test: Monitor platelet, white blood cell and red blood cell counts to ensure the blood count is within a safe range.

Liver function test: Regularly check liver enzyme levels to prevent liver function abnormalities.

Electrocardiogram examination: Some patients may have abnormal heart rate, and electrocardiogram monitoring is required if necessary.

Blood pressure monitoring: Measure blood pressure regularly, especially in patients with a history of hypertension.

7.Drug Interactions

Aximinib has potential interactions with a variety of drugs, including:

CYP3A4 inhibitors (such as ketoconazole, itraconazole): may increase the plasma concentration of aceminib, and the dose needs to be adjusted.

CYP3A4Inducers (e.g., rifampicin, phenytoin): may reduce the efficacy of aceminib.

Antacids: such as proton pump inhibitors, H2 receptor antagonists, etc., may affect the absorption of aceminib. Avoid using these drugs at the same time when taking the drug.

8.Storage conditions

Aximini should be stored in a dry, cool place, away from direct sunlight, and kept at a temperature between 15℃ and 30℃.

Medicines should be kept away from children and pets to avoid accidental ingestion.

9.Precautions after taking medicine

While taking Asiminib, patients should have regular follow-up visits to monitor disease progression and drug side effects. If any discomfort or serious side effects occur, you should contact your doctor promptly.

Patients should not adjust the dosage or stop taking the medicine without authorization, and should consult their doctor before stopping the medicine.

Aximinib is an effective treatment for chronic myelogenous leukemia, especially for patients who are resistant to otherTKI or intolerant of side effects. Although the drug has significant efficacy, patients need to closely monitor adverse reactions during use and strictly follow the doctor's recommendations for dose adjustment and side effect management.